Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 7/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564959 | 0.85 | SLC6A2 (0.38) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL18393163 | 0.83 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2874872 | 0.77 | ADH1B (0.32) | — | |
| SCHEMBL1563996 | 0.76 | GAA (0.33) | — | |
| SCHEMBL1564328 | 0.75 | BDKRB2 (0.43) | — | |
| Hydrochloric Acid SCHEMBL1563435 | 0.74 | PDE4D (0.33) | — | |
| Hydrochloric Acid SCHEMBL2872100 | 0.74 | BDKRB2 (0.42) | — | |
| Hydrochloric Acid SCHEMBL6627836 | 0.74 | GAA (0.32) | — | |
| SCHEMBL5768459 | 0.71 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5769191 | 0.71 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410134-B2 | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2144897-B1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2144897-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | Jerini AG (DE) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008116620-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234344-A1 | 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | BDKRB2, BDKRB1, HRH2 | SLC6A4 836/4885SLC6A2 475/4885SLC6A3 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.